comp_molregno,act_standard_units,act_standard_type,act_activity_comment,act_bao_endpoint,act_type,ass_assay_id,ass_description,ass_assay_type,ass_assay_category,ass_chembl_id,doc_doi,doc_pubmed_id,doc_chembl_id,doc_title,doc_doc_type,doc_abstract,doc_patent_id,coms_canonical_smiles,comp_full_molformula,mold_chembl_id,act_0,act_1,act_2
1613763,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(Cl)c3)c(C(=O)c3cccc(Cl)c3)s2)cc1,C27H21Cl2NO4S2,CHEMBL3105669,89.0,,
1613764,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(Cl)c3)c(C(=O)c3ccccc3F)s2)cc1,C27H21ClFNO4S2,CHEMBL3105670,106.0,,
1613765,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(Cl)c3)c(C(=O)c3cccc(F)c3)s2)cc1,C27H21ClFNO4S2,CHEMBL3105671,104.0,,
1613766,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(C(F)(F)F)c3)c(C(=O)c3cccc(F)c3)s2)cc1,C28H21F4NO4S2,CHEMBL3105672,104.0,,
1613767,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)C3CCCCC3)s2)cc1,C26H28N2O4S2,CHEMBL3105673,87.0,,
1613768,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, ",%max,"Entry 0: 1285943, Entry 1: 1729707, Entry 2: 1729709, ","Entry 0: Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay, Entry 1: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 2: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3106086, Entry 1: CHEMBL4144985, Entry 2: CHEMBL4144987, ","Entry 0: 10.1016/j.bmc.2013.12.021, Entry 1: 10.1021/acsmedchemlett.7b00476, Entry 2: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 24388993, Entry 1: 29456799, Entry 2: 29456799, ","Entry 0: CHEMBL3102747, Entry 1: CHEMBL4138302, Entry 2: CHEMBL4138302, ","Entry 0: Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 2: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 2: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)c3ccccc3)s2)cc1,C26H22N2O4S2,CHEMBL3105674,51.0,98.0,107.0
1613769,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3Cl)c(C(=O)c3ccccc3)s2)cc1,C26H21ClN2O4S2,CHEMBL3105675,90.0,,
1613770,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)c(C(=O)c3ccccc3)s2)cc1,C26H21ClN2O4S2,CHEMBL3105676,100.0,,
1613771,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccc(Cl)cc3)c(C(=O)c3ccccc3)s2)cc1,C26H21ClN2O4S2,CHEMBL3105677,102.0,,
1613772,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(C#N)c3)c(C(=O)c3ccccc3)s2)cc1,C27H21N3O4S2,CHEMBL3105678,101.0,,
1613773,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(CN(C)C)c3)c(C(=O)c3ccccc3)s2)cc1,C29H29N3O4S2,CHEMBL3105679,105.0,,
1613774,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(C(=O)O)c3)c(C(=O)c3ccccc3)s2)cc1,C27H22N2O6S2,CHEMBL3105680,80.0,,
1613775,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)c(C(=O)c3ccccc3Cl)s2)cc1,C26H20Cl2N2O4S2,CHEMBL3105681,97.0,,
1613776,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)c(C(=O)c3cccc(Cl)c3)s2)cc1,C26H20Cl2N2O4S2,CHEMBL3105682,85.0,,
1613777,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)c(C(=O)c3ccc(Cl)cc3)s2)cc1,C26H20Cl2N2O4S2,CHEMBL3105683,76.0,,
1613778,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)c(C(=O)c3ccccc3F)s2)cc1,C26H20ClFN2O4S2,CHEMBL3105684,102.0,,
1613779,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)c(C(=O)c3cccc(F)c3)s2)cc1,C26H20ClFN2O4S2,CHEMBL3105685,102.0,,
1613780,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3ccccc3)c(C(=O)c3ccccc3)s2)cc1,C27H23NO4S2,CHEMBL3105686,103.0,,
1613784,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(Cl)c3)c(C(=O)c3ccccc3)s2)cc1,C27H22ClNO4S2,CHEMBL3105690,99.0,,
1613785,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(C#N)c3)c(C(=O)c3ccccc3)s2)cc1,C28H22N2O4S2,CHEMBL3105691,101.0,,
1613786,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2cc(-c3cccc(Cl)c3)c(C(=O)c3ccccc3Cl)s2)cc1,C27H21Cl2NO4S2,CHEMBL3105692,105.0,,
1613789,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(C3CCCCC3)cs2)cc1,C19H24N2O3S2,CHEMBL3105695,105.0,,
1613889,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)cs2)cc1,C19H18N2O3S2,CHEMBL3105794,74.0,,
1613890,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3Cl)cs2)cc1,C19H17ClN2O3S2,CHEMBL3105795,116.0,,
1613891,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3)cs2)cc1,C19H17ClN2O3S2,CHEMBL3105796,111.0,,
1613892,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccc(Cl)cc3)cs2)cc1,C19H17ClN2O3S2,CHEMBL3105797,100.0,,
1613893,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cccc(Cl)c3Cl)cs2)cc1,C19H16Cl2N2O3S2,CHEMBL3105798,119.0,,
1613894,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccc(Cl)cc3Cl)cs2)cc1,C19H16Cl2N2O3S2,CHEMBL3105799,119.0,,
1613895,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3c(Cl)cccc3Cl)cs2)cc1,C19H16Cl2N2O3S2,CHEMBL3105800,120.0,,
1613896,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C)s2)cc1,C20H20N2O3S2,CHEMBL3105801,99.0,,
1613897,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCc1sc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)nc1-c1ccccc1,C21H22N2O3S2,CHEMBL3105802,120.0,,
1613898,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(C)C)s2)cc1,C22H24N2O3S2,CHEMBL3105803,118.0,,
1613899,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(Cc3ccccc3)s2)cc1,C26H24N2O3S2,CHEMBL3105804,92.0,,
1613900,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(Oc3ccccc3)s2)cc1,C25H22N2O4S2,CHEMBL3102888,104.0,,
1613901,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)OC)s2)cc1,C21H20N2O5S2,CHEMBL3105805,74.0,,
1613902,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(C)=O)s2)cc1,C21H20N2O4S2,CHEMBL3105806,97.0,,
1613903,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCC(=O)c1sc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)nc1-c1ccccc1,C22H22N2O4S2,CHEMBL3105807,86.0,,
1613907,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,O=C(Cc1ccccc1)Nc1nc(-c2cc(Cl)ccc2Cl)cs1,C17H12Cl2N2OS,CHEMBL3105811,71.0,,
1613908,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,O=C(Cc1ccc(Cl)cc1)Nc1nc(-c2cc(Cl)ccc2Cl)cs1,C17H11Cl3N2OS,CHEMBL3105812,80.0,,
1613909,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,N#Cc1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C18H11Cl2N3OS,CHEMBL3105813,110.0,,
1613910,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C18H14Cl2N2O3S2,CHEMBL3105814,117.0,,
1613911,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, Entry 2: BAO_0000179, ",%max,"Entry 0: 1285943, Entry 1: 1288037, Entry 2: 1288039, ","Entry 0: Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay, Entry 1: Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control, Entry 2: Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide, ","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3106086, Entry 1: CHEMBL3110540, Entry 2: CHEMBL3110542, ","Entry 0: 10.1016/j.bmc.2013.12.021, Entry 1: 10.1021/ml4003875, Entry 2: 10.1021/ml4003875, ","Entry 0: 24388993, Entry 1: 24900774, Entry 2: 24900774, ","Entry 0: CHEMBL3102747, Entry 1: CHEMBL3108708, Entry 2: CHEMBL3108708, ","Entry 0: Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors., Entry 1: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., Entry 2: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration., Entry 1: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., Entry 2: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C19H16Cl2N2O3S2,CHEMBL3105815,91.0,116.0,116.0
1613912,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CCCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C20H18Cl2N2O3S2,CHEMBL3105816,92.0,,
1613913,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CC(C)S(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C20H18Cl2N2O3S2,CHEMBL3105817,80.0,,
1613915,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CNS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C18H15Cl2N3O3S2,CHEMBL3105819,111.0,,
1613916,%,%max,,BAO_0000179,%max,1285943,"Inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced APC-labeled RORgammat receptor ligand binding domain (unknown origin) after 1 hr by FRET assay",B,,CHEMBL3106086,10.1016/j.bmc.2013.12.021,24388993,CHEMBL3102747,Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors.,PUBLICATION,Novel series of N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides were discovered as potent retinoic acid receptor-related orphan receptor-gamma-t (RORγt) inhibitors. SAR studies of the RORγt HTS hit 6a led to identification of thiazole ketone amide 8h and thiophene ketone amide 9g with high binding affinity and inhibitory activity of Th17 cell differentiation. Compound 8h showed in vivo efficacy in both mouse experimental autoimmune encephalomyelitis (EAE) and collagen induced arthritis (CIA) models via oral administration.,,CN(C)S(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3cc(Cl)ccc3Cl)cs2)cc1,C19H17Cl2N3O3S2,CHEMBL3105820,80.0,,
1614420,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1288037, Entry 1: 1288039, ","Entry 0: Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control, Entry 1: Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3110540, Entry 1: CHEMBL3110542, ","Entry 0: 10.1021/ml4003875, Entry 1: 10.1021/ml4003875, ","Entry 0: 24900774, Entry 1: 24900774, ","Entry 0: CHEMBL3108708, Entry 1: CHEMBL3108708, ","Entry 0: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., Entry 1: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., Entry 1: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., ",,CCCN(Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1)Cc1ccc(-c2ccccc2)cc1,C33H36N2O3S,CHEMBL3109222,94.0,115.0,
1614421,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(CNCc3ccc(C(F)(F)F)cc3)cc2)cc1,C25H25F3N2O3S,CHEMBL3109223,115.0,,
1614422,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(NCCc3ccc(C(F)(F)F)cc3)cc2)cc1,C25H25F3N2O3S,CHEMBL3109224,117.0,,
1614423,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCCN(CCc1ccc(C(F)(F)F)cc1)c1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1,C28H31F3N2O3S,CHEMBL3109225,113.0,,
1614424,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(NCCc3ccc(C(F)(F)F)cc3)c(Cl)c2)cc1,C25H24ClF3N2O3S,CHEMBL3109226,109.0,,
1614425,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(C(F)(F)F)cc3)c2)cc1,C27H25F3N2O3S,CHEMBL3109227,104.0,,
1614426,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccccc3)c2)cc1,C26H26N2O3S,CHEMBL3109228,65.0,,
1614427,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(F)cc3)c2)cc1,C26H25FN2O3S,CHEMBL3109229,92.0,,
1614428,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(Cl)cc3)c2)cc1,C26H25ClN2O3S,CHEMBL3109230,99.0,,
1614429,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(C#N)cc3)c2)cc1,C27H25N3O3S,CHEMBL3109231,108.0,,
1614430,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(OC(C)C)cc3)c2)cc1,C29H32N2O4S,CHEMBL3109232,119.0,,
1614431,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccccc3C(F)(F)F)c2)cc1,C27H25F3N2O3S,CHEMBL3109233,83.0,,
1614432,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3cccc(C(F)(F)F)c3)c2)cc1,C27H25F3N2O3S,CHEMBL3109234,57.0,,
1614433,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(Cl)cc3Cl)c2)cc1,C26H24Cl2N2O3S,CHEMBL3109235,100.0,,
1614523,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc3c(ccn3CCc3ccc(Cl)c(Cl)c3)c2)cc1,C26H24Cl2N2O3S,CHEMBL3109324,98.0,,
1614524,%,%max,,BAO_0000179,%max,1288037,Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control,B,,CHEMBL3110540,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCCN(Cc1ccccc1)Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1,C27H32N2O3S,CHEMBL3109325,125.0,,
1614525,%,%max,,BAO_0000179,%max,1288037,Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control,B,,CHEMBL3110540,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCCN(Cc1ccc(C)cc1)Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1,C28H34N2O3S,CHEMBL3109326,89.0,,
1614526,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1288037, Entry 1: 1288039, ","Entry 0: Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control, Entry 1: Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3110540, Entry 1: CHEMBL3110542, ","Entry 0: 10.1021/ml4003875, Entry 1: 10.1021/ml4003875, ","Entry 0: 24900774, Entry 1: 24900774, ","Entry 0: CHEMBL3108708, Entry 1: CHEMBL3108708, ","Entry 0: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., Entry 1: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., Entry 1: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., ",,CCCN(Cc1ccc(CC)cc1)Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1,C29H36N2O3S,CHEMBL3109327,38.0,65.0,
1614527,%,%max,,BAO_0000179,%max,1288039,"Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide",B,,CHEMBL3110542,10.1021/ml4003875,24900774,CHEMBL3108708,Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists.,PUBLICATION,A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists.,,CCCN(Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1)Cc1ccc(C(C)(C)C)cc1,C31H40N2O3S,CHEMBL3109328,84.0,,
1614528,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1288037, Entry 1: 1288039, ","Entry 0: Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control, Entry 1: Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3110540, Entry 1: CHEMBL3110542, ","Entry 0: 10.1021/ml4003875, Entry 1: 10.1021/ml4003875, ","Entry 0: 24900774, Entry 1: 24900774, ","Entry 0: CHEMBL3108708, Entry 1: CHEMBL3108708, ","Entry 0: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., Entry 1: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., Entry 1: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., ",,CCCN(Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1)Cc1ccc(C(F)(F)F)cc1,C28H31F3N2O3S,CHEMBL3109329,25.0,92.0,
1614529,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1288037, Entry 1: 1288039, ","Entry 0: Inverse agonist activity at biotinylated human RORgammat expressed in Escherichia coli BL21 assessed as effect on recruitment of SRC1/2 after 1 hr by dual-FRET assay relative to control, Entry 1: Inverse agonist activity at biotinylated human RORgammat LBD expressed in Escherichia coli BL21 assessed as inhibition of SRC1 recruitment after 1 hr by FRET assay relative to control in presence of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3110540, Entry 1: CHEMBL3110542, ","Entry 0: 10.1021/ml4003875, Entry 1: 10.1021/ml4003875, ","Entry 0: 24900774, Entry 1: 24900774, ","Entry 0: CHEMBL3108708, Entry 1: CHEMBL3108708, ","Entry 0: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., Entry 1: Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., Entry 1: A novel series of tertiary amines as retinoid-related orphan receptor gamma-t (RORγt) inverse agonists was discovered through agonist/inverse agonist conversion. The level of RORγt inhibition can be enhanced by modulating the conformational disruption of H12 in RORγt LBD. Linker exploration and rational design led to the discovery of more potent indole-based RORγt inverse agonists., ",,CCCN(Cc1ccc(NC(=O)Cc2ccc(S(=O)(=O)CC)cc2)cc1)Cc1ccc(OC2CCCC2)cc1,C32H40N2O4S,CHEMBL3109330,85.0,115.0,
1960255,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccccc3C(F)(F)F)c(Cl)c2)cc1,C23H19ClF3NO3S,CHEMBL3609392,45.0,104.0,
2262114,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(CC4CCN(C(C)=O)CC4)c(C#N)c3)c(C(F)(F)F)c2)cc1,C32H32F3N3O4S,CHEMBL4159083,35.0,95.0,
2263965,%,%max,,BAO_0000179,%max,1729711,Agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control,B,,CHEMBL4144989,10.1021/acsmedchemlett.7b00476,29456799,CHEMBL4138302,From RORγt Agonist to Two Types of RORγt Inverse Agonists.,PUBLICATION,"Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.",,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)c3ccccc3C(C)C)s2)cc1,C29H28N2O4S2,CHEMBL4160934,94.0,,
2264380,%,%max,,BAO_0000179,%max,1729711,Agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control,B,,CHEMBL4144989,10.1021/acsmedchemlett.7b00476,29456799,CHEMBL4138302,From RORγt Agonist to Two Types of RORγt Inverse Agonists.,PUBLICATION,"Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.",,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)c3ccccc3CC(C)C)s2)cc1,C30H30N2O4S2,CHEMBL4161349,157.0,,
2266257,%,%max,,BAO_0000179,%max,1729707,"Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control",B,,CHEMBL4144985,10.1021/acsmedchemlett.7b00476,29456799,CHEMBL4138302,From RORγt Agonist to Two Types of RORγt Inverse Agonists.,PUBLICATION,"Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3cccc(C#N)c3)c(C(F)(F)F)c2)cc1,C24H19F3N2O3S,CHEMBL4163226,58.0,,
2266564,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(CC4CCN(C(=O)C(C)(C)C)CC4)c(C#N)c3)c(C(F)(F)F)c2)cc1,C35H38F3N3O4S,CHEMBL4163533,120.0,121.0,
2267797,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(C(C)C)c(C(F)(F)F)c2)cc1,C20H22F3NO3S,CHEMBL4164766,64.0,114.0,
2270015,%,%max,,BAO_0000179,%max,1729707,"Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control",B,,CHEMBL4144985,10.1021/acsmedchemlett.7b00476,29456799,CHEMBL4138302,From RORγt Agonist to Two Types of RORγt Inverse Agonists.,PUBLICATION,"Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(CC4CCCCC4)c(C#N)c3)c(C(F)(F)F)c2)cc1,C31H31F3N2O3S,CHEMBL4166984,80.0,,
2272307,%,%max,,BAO_0000179,%max,1729711,Agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control,B,,CHEMBL4144989,10.1021/acsmedchemlett.7b00476,29456799,CHEMBL4138302,From RORγt Agonist to Two Types of RORγt Inverse Agonists.,PUBLICATION,"Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.",,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)c3ccccc3C3CCCC3)s2)cc1,C31H30N2O4S2,CHEMBL4169276,206.0,,
2274173,%,%max,,BAO_0000179,%max,1729711,Agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control,B,,CHEMBL4144989,10.1021/acsmedchemlett.7b00476,29456799,CHEMBL4138302,From RORγt Agonist to Two Types of RORγt Inverse Agonists.,PUBLICATION,"Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology.",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(CC(C)C)c(C#N)c3)c(C(F)(F)F)c2)cc1,C28H27F3N2O3S,CHEMBL4171142,199.0,,
2274578,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2nc(-c3ccccc3)c(C(=O)c3ccccc3C)s2)cc1,C27H24N2O4S2,CHEMBL4171547,51.0,99.0,
2275696,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccccc3)c(C(F)(F)F)c2)cc1,C23H20F3NO3S,CHEMBL4172665,40.0,97.0,
2276861,%,%max,,"Entry 0: BAO_0000179, Entry 1: BAO_0000179, ",%max,"Entry 0: 1729707, Entry 1: 1729709, ","Entry 0: Inverse agonist activity at APC-labeled RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by FRET based LANCE assay relative to control, Entry 1: Inverse agonist activity at biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((2'-methoxy-[1,1'-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator SRC1 peptide recruitment after 1 hr by dual FRET based LANCE assay relative to control, ","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4144985, Entry 1: CHEMBL4144987, ","Entry 0: 10.1021/acsmedchemlett.7b00476, Entry 1: 10.1021/acsmedchemlett.7b00476, ","Entry 0: 29456799, Entry 1: 29456799, ","Entry 0: CHEMBL4138302, Entry 1: CHEMBL4138302, ","Entry 0: From RORγt Agonist to Two Types of RORγt Inverse Agonists., Entry 1: From RORγt Agonist to Two Types of RORγt Inverse Agonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., Entry 1: Biaryl amides as new RORγt modulators were discovered. The crystal structure of biaryl amide agonist 6 in complex with RORγt ligand binding domain (LBD) was resolved, and both ""short"" and ""long"" inverse agonists were obtained by removing from 6 or adding to 6 a proper structural moiety. While ""short"" inverse agonist (8) recruits a corepressor peptide and dispels a coactivator peptide, ""long"" inverse agonist (9) dispels both. The two types of inverse agonists can be utilized as potential tools to study mechanisms of Th17 transcriptional network inhibition and related disease biology., ",,CCS(=O)(=O)c1ccc(CC(=O)Nc2ccc(-c3ccc(CC4CCN(C(=O)C(C)(C)C)CC4)cc3C(F)(F)F)c(Cl)c2)cc1,C34H38ClF3N2O4S,CHEMBL4173830,86.0,118.0,
2343347,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)C2CCCCC2)CC3)c1,C30H34N4O2,CHEMBL4436338,119.2,,
2346293,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)CC2CCC2)c1,C29H32N4O2,CHEMBL4439284,146.4,,
2346298,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc3c2CCC3N2CCN(C(=O)C3CCCC3)CC2)c1,C27H30N4O2,CHEMBL4439289,149.0,,
2348610,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)C2CCCCC2)c1,C30H34N4O2,CHEMBL4441601,166.7,,
2348623,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,C[C@H]1CN(C2CCc3c(NC(=O)c4cccc(C#N)c4)cccc32)CCN1C(=O)C1CCCC1,C28H32N4O2,CHEMBL4441614,151.8,,
2351467,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,C[C@@H]1CN(C2CCc3ccc(NC(=O)c4cccc(C#N)c4)cc32)CCN1C(=O)C1CCCC1,C28H32N4O2,CHEMBL4444458,124.0,,
2351468,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,Cn1cc(C2CCN(C(=O)C3CCCC3)CC2)c2cccc(NC(=O)c3cccc(C#N)c3)c21,C28H30N4O2,CHEMBL4444459,108.7,,
2359657,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,C[C@@H]1CN(C2CCc3c(NC(=O)c4cccc(C#N)c4)cccc32)CCN1C(=O)C1CCCC1,C28H32N4O2,CHEMBL4452648,146.4,,
2363681,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,C[C@H]1CN(C2CCc3ccc(NC(=O)c4cccc(C#N)c4)cc32)C[C@@H](C)N1C(=O)C1CCCC1,C29H34N4O2,CHEMBL4456672,122.3,,
2364865,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc3c2CCN3C2CCN(C(=O)C3CCCC3)CC2)c1,C27H30N4O2,CHEMBL4457856,129.7,,
2370696,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(NC(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)C2CCCC2)c1,C29H33N5O2,CHEMBL4463687,114.1,,
2371283,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,O=C(CC1CCOCC1)Nc1ccc2c(c1)C(N1CC3CCC(C1)N3C(=O)C1CCCC1)CC2,C28H39N3O3,CHEMBL4464274,140.1,,
2375873,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)[C@@H](N2CC4CCC(C2)N4C(=O)C2CCCCC2)CC3)c1,C30H34N4O2,CHEMBL4468864,137.3,,
2377780,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,Cc1ccc(C(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)C2CCCC2)cn1,C28H34N4O2,CHEMBL4470771,156.5,,
2381346,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)C2CCCC2)CC3)c1,C29H32N4O2,CHEMBL4474340,147.4,,
2382305,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)C2CCC2)c1,C28H30N4O2,CHEMBL4475299,144.3,,
2383213,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)CC2CCC2)CC3)c1,C29H32N4O2,CHEMBL4476207,148.9,,
2384963,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)C2CCC2)CC3)c1,C28H30N4O2,CHEMBL4513552,141.6,,
2386690,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,Cc1ncc(C(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)C2CCCC2)cc1F,C28H33FN4O2,CHEMBL4515279,142.3,,
2395246,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)N(C2CCN(C(=O)C4CCCC4)CC2)CC3)c1,C27H30N4O2,CHEMBL4524815,156.2,,
2397795,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,Cc1ccc(C(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)C2CCCC2)CC3)cn1,C28H34N4O2,CHEMBL4527364,148.1,,
2403528,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3c(c2)C(N2CCN(C(=O)C4CCCC4)CC2)CC3)c1,C27H30N4O2,CHEMBL4533097,107.7,,
2410223,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2ccc3ccn(C4CCN(C(=O)C5CCCC5)CC4)c3c2)c1,C27H28N4O2,CHEMBL4539792,137.8,,
2414761,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,Cc1ncc(C(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)C2CCCC2)CC3)cc1F,C28H33FN4O2,CHEMBL4544333,141.5,,
2416918,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,O=C(CC1CCOCC1)Nc1cccc2c1CCC2N1CC2CCC(C1)N2C(=O)C1CCCC1,C28H39N3O3,CHEMBL4546490,92.8,,
2419998,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc(CN3CCN(C(=O)C4CCCC4)CC3)c2)c1,C25H28N4O2,CHEMBL4549570,135.9,,
2434605,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,C[C@H]1CN(C2CCc3c(NC(=O)c4cccc(C#N)c4)cccc32)C[C@@H](C)N1C(=O)C1CCCC1,C29H34N4O2,CHEMBL4564177,148.9,,
2447132,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(C(=O)Nc2cccc3c2CCC3N2CC3CCC(C2)N3C(=O)C2CCCC2)c1,C29H32N4O2,CHEMBL4576701,144.3,,
2459056,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,C[C@H]1CN(C2CCc3ccc(NC(=O)c4cccc(C#N)c4)cc32)CCN1C(=O)C1CCCC1,C28H32N4O2,CHEMBL4588625,118.3,,
2463217,%,%max,,BAO_0000179,%max,1839071,"Inverse agonist activity at APC-labeled biotinylated RORgammat LBD (unknown origin) assessed as inhibition of N-(2-chloro-6-fluorobenzyl)-N-((20-methoxy-[1,10-biphenyl]-4-yl)methyl)benzenesulfonamide-induced co-activator europium-labeled biotinylated SRC1 peptide recruitment after 1 hr by LANCE-FRET assay relative to control",B,,CHEMBL4339286,10.1016/j.ejmech.2019.01.082,30743096,CHEMBL4339183,Discovery of N-indanyl benzamides as potent RORγt inverse agonists.,PUBLICATION,"The retinoic acid receptor-related orphan receptor-gamma-t (RORγt) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel RORγt inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent RORγt inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule RORγt inverse agonists. Binding modes of the two enantiomers 5c and 5d in RORγt ligand binding domain were also discussed.",,N#Cc1cccc(NC(=O)Nc2ccc3c(c2)C(N2CC4CCC(C2)N4C(=O)C2CCCC2)CC3)c1,C29H33N5O2,CHEMBL4592786,134.2,,
